For the record I'm long on AFFY but I have a simple question...
Assuming AFFY makes it back to market, what are the medical benefits that would make a dr prescribe AFFY over Epogen? Are there patients who responded poorly to Epogen but reacted better to AFFY? Or are these medications essentially the same (6 one 1/2 doz another)?
Let me give you my 2 cents, i am working with renal patients more than 75% of renal pts here in the u.s.are medicare/medicaids,one of the reasons why omontys plays a very important roles in dialysis business is cost effective,this medicine can only be given once a month,its a long acting medication compare to epogen which is very expensive and most of the time will be given every treatment(dialysis),medical claims on renal care is increasing exponentially for this reason the government had come up with the plans of what they called the bundling system,setting up a specific budget for dialysis treatment,substantial amount of earnings was cut off thereby making some huge adjustments necessary for the business to survive,the point of the matter is someway somehow they are going to work it out to bring omontys back to renal care,we are dealing with end stage renal disease! Dependency for dialysis is for life not unless they get a successful transplant, omontys willsave billions of dollars on medical claims,i hope the competitors product will not come into play.
For the record, I am short AFFY and have been since before O's recall. O has no medical benefits over Epogen/Aranesp/Procrit. O's efficacy is "non-inferior", meaning no better than the competing medicines. O's ONLY benefit is the CONVENIENCE of "once monthly" dosing, hence the name Omontys. O's convenience benefit, however, is lost on CKD patients on dialysis who are diffused 3x weekly at the clinic. Moreover, in 2014, Roche's Micera will be allowed in the US market (its US use was blocked until then as part of Amgen patent dispute). Micera is dosed once every 3 to 4 weeks so its entry into the US market is expected to significantly undercut any perceived O convenience advantage.
I might also add that Epogen/Aranesp/Procrit/Micera are FDA approved for to treat anemia in ALL CKD patients. Only O is limited to CKD patients on dialysis because the PEARL studies, paradoxically, proved O was unsafe for the healthier CKD patients not on dialysis. Why that is so remains unexplained.